Overview

Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in Type 1 diabetes patients. Participants will use continuous glucose monitoring to measure the sugar levels in their blood, and work with the doctor to find the best doses. One group of patients will get the liver targeting insulin, and the other group will use insulin they normally use for treating Type 1 diabetes. The participant will be part of the study for up to 32 weeks.

Phase:

PHASE2

Details

Lead Sponsor:

Diasome Pharmaceuticlas, Inc.

Treatments:

Insulin Lispro